Abstract
A structurally optimised farnesoid X receptor (FXR) agonist, MET409, reduces liver fat content in patients with non-alcoholic steatohepatitis (NASH), new research suggests. Stephen Harrison and colleagues randomly assigned patients with NASH to receive MET409 80 mg (n=20), 50 mg (n=19), or placebo (n=19). MET409 lowered liver fat content with a mean relative reduction of 55% in the 80 mg group and 38% in 50 mg group, compared with 6% in the placebo group (p<0·001). MET409 achieved a 30% or greater relative reduction in liver fat content in 13 (93%) of 14 patients in the 80 mg group and 12 (75%) of 16 patients in the 50 mg group compared with two (11%) of 18 in the placebo group (p<0·001).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
